These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17785966)

  • 1. Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.
    Kanke K; Hoshino M; Tominaga K; Nakano M; Terano A; Hiraishi H
    Blood Purif; 2007; 25(4):370-6. PubMed ID: 17785966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
    Sawada K; Ohdo M; Ino T; Nakamura T; Numata T; Shibata H; Sakou J; Kusada M; Hibi T
    Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
    Ashizuka S; Nishiura R; Ishikawa N; Yamaga J; Inatsu H; Fujimoto S; Eto T
    Ther Apher Dial; 2006 Feb; 10(1):54-8. PubMed ID: 16556137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of various anticoagulant agents on large-volume leukocytapheresis using new Cellsorba CS-180S Filter.
    Hohtatsu K; Yamaji K; Yamada R; Oda K; Kageyama M; Kusaoi M; Onuma S; Kawamoto T; Sugimoto K; Sekiya F; Kon T; Ogasawara M; Kempe K; Tsuda H; Takasaki Y
    Ther Apher Dial; 2011 Aug; 15(4):355-9. PubMed ID: 21884469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study.
    Sakata Y; Iwakiri R; Amemori S; Yamaguchi K; Fujise T; Otani H; Shimoda R; Tsunada S; Sakata H; Ikeda Y; Ando T; Nakafusa Y; Fujimoto K
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):629-33. PubMed ID: 18679064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
    Sawada K; Kusugami K; Suzuki Y; Bamba T; Munakata A; Hibi T; Shimoyama T
    Am J Gastroenterol; 2005 Jun; 100(6):1362-9. PubMed ID: 15929771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of leukocytapheresis therapy for ulcerative colitis on anemia and hemodynamics.
    Miyamoto H; Okahisa T; Iwaki H; Murata M; Ito S; Nitta Y; Akutagawa M; Kinouchi Y; Ohnishi Y; Oto J; Nishimura M
    Ther Apher Dial; 2007 Feb; 11(1):16-21. PubMed ID: 17309570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis.
    Shimada M; Iwase H; Tsuzuki T; Hirashima N; Kobayashi K; Hibino Y; Watanabe H; Ryuge N; Ando T; Goto H; Yagi Y; Tsujikawa T; Andoh A
    Ther Apher Dial; 2008 Oct; 12(5):368-73. PubMed ID: 18937719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy.
    Nishioka C; Aoyama N; Maekawa S; Shirasaka D; Nakahara T; Tamura T; Fukagawa M; Umezu M; Abe T; Kasuga M
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1567-71. PubMed ID: 16174075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in bradykinin generation during leukocytapheresis using novel cellsorba(TM) CS-180S: Effects of changing the filling solution.
    Yamada R; Kusaoi M; Murayama G; Yasui M; Hishinuma R; Nemoto T; Hohtatsu K; Kageyama M; Kawamoto T; Sugimoto K; Sekiya F; Kon T; Ogasawara M; Kempe K; Yamaji K; Tsuda H; Takasaki Y
    J Clin Apher; 2014 Apr; 29(2):90-6. PubMed ID: 24023037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.
    Fukunaga K; Kamikozuru K; Yokoyama Y; Hida N; Ohda Y; Takeda N; Yoshida K; Iimuro M; Kikuyama R; Kato K; Nagase K; Nakamura S; Miwa H; Matsumoto T
    J Clin Apher; 2011 Dec; 26(6):326-31. PubMed ID: 22083887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant.
    Nagase K; Fukunaga K; Ohnishi K; Kusaka T; Matoba Y; Sawada K
    Ther Apher Dial; 2004 Feb; 8(1):45-51. PubMed ID: 15128019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis.
    Sawada K; Ohnishi K; Kosaka T; Chikano S; Yokota Y; Egashira A; Izawa H; Yamamura M; Amano K; Satomi M; Shimoyama T
    Ther Apher; 1997 Aug; 1(3):207-11. PubMed ID: 10225739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Leukocytapheresis for ulcerative colitis].
    Fukunaga K; Sawada K; Chikano S; Ohnishi K; Egashira A; Tanaka J; Nagase K; Satomi M; Shimoyama T
    Nihon Rinsho; 1999 Nov; 57(11):2496-502. PubMed ID: 10572419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications of leukocytapheresis.
    Nagase K; Sawada K; Ohnishi K; Egashira A; Ohkusu K; Shimoyama T
    Ther Apher; 1998 May; 2(2):120-4. PubMed ID: 10225712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of leukocytapheresis in suppressing the occurrence of surgical site infections following surgery for ulcerative colitis.
    Itabashi M; Ikeuchi H; Araki T; Kono T; Nakamura T; Takesue Y; Kameoka S; Kusunoki M
    Surg Today; 2008; 38(7):609-17. PubMed ID: 18612785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study.
    Zezos P; Papaioannou G; Nikolaidis N; Patsiaoura K; Papageorgiou A; Vassiliadis T; Giouleme O; Evgenidis N
    Aliment Pharmacol Ther; 2006 May; 23(10):1443-53. PubMed ID: 16669959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis.
    Ashida T; Kohgo Y; Munakata A; Noguchi M; Iizuka B; Endo Y; Hanai H; Yoshikawa T; Matsumoto T; Aoyama N; Matsui T; Mitsuyama K; Hibi T
    Transfus Apher Sci; 2011 Apr; 44(2):113-7. PubMed ID: 21402309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukocytapheresis using a leukocyte removal filter.
    Shirokaze J
    Ther Apher; 2002 Aug; 6(4):261-6. PubMed ID: 12164794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis.
    Shen J; Ran ZH; Tong JL; Xiao SD
    Aliment Pharmacol Ther; 2007 Sep; 26(5):653-63. PubMed ID: 17697199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.